Dongsung Pharmaceutical Co. Ltd. announced that it expects to receive KRW 10 billion in funding from Synergy Partners Co., Ltd., Golden Bridge Asset Management Co., Ltd., Susung Asset Management Co., Ltd., NH Investment & Securities Co., Ltd., Investment Arm
July 10, 2016
Share
Dongsung Pharmaceutical Co. Ltd. (KOSE:A002210) announced a private placement of 30th unregistered unsecured coupon unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on July 11, 2016. The bonds will be issued at its par value. The transaction will include participation from new investors, Synergy Partners Co., Ltd., GB Synergy Mezzanine Private Fund and GB Synergy Mezzanine Specialty Investment Private Fund, funds managed by Golden Bridge Asset Management Co., Ltd., Susung Asset Management Co., Ltd., and NH Investment & Securities Co., Ltd. for KRW 4,300,000,000, KRW 2,200,000,000, KRW 1,500,000,000, KRW 1,000,000,000, and KRW 1,000,000,000. The bonds will not carry any interest or any annual coupon. The bonds will mature on July 12, 2021. The bonds will be fully convertible into registered common shares of the company at a conversion price of KRW 6,073 per share. The conversion period of the bonds will be from July 12, 2017 to June 12, 2021. The payment date for the bonds is expected on July 12, 2016. The transaction was approved by the board of directors of the company.
Dongsung Pharmaceutical Co., Ltd. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include anti-rheumatic, anti-inflammatory analgesics, anti-inflammatory enzymes, drugs for cardiovascular system, gastrointestinal drugs, antispasmodic agents, respiratory agents, anti-histamine, dermatologicals, antibiotics, antidiarrheals, antifungals, oral hypoglycemic agents, hormones, hypnotics and others. It also produces hair dyes and cosmetics. The Company distributes its products within domestic market and to overseas markets.
Dongsung Pharmaceutical Co. Ltd. announced that it expects to receive KRW 10 billion in funding from Synergy Partners Co., Ltd., Golden Bridge Asset Management Co., Ltd., Susung Asset Management Co., Ltd., NH Investment & Securities Co., Ltd., Investment Arm